ReviewFrontiers in health services2025
The uphill journey of smoking cessation in chronic obstructive pulmonary disease: why a well-built vehicle matters.
Review in Frontiers in health services, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- E-cigarette use among individuals with chronic obstructive pulmonary disease.Internal and emergency medicine · 2026Article
- The right time to quit: patients' experiences of smoking cessation support during COPD hospitalisation.Health psychology and behavioral medicine · 2026Article
- Development and Psychometric Evaluation of a Pulmonary Rehabilitation Information Needs Scale for Patients with Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Smoking cessation remains among the most effective interventions for improving outcomes in patients with chronic obstructive pulmonary disease (COPD). Quitting smoking slows disease progression, reduces morbidity, improves quality of life and increases life expectancy. However, a substantial proportion of patients with COPD continue to smoke, and generic cessation strategies often fall short in this population. While most cessation research targets "healthy" smokers, individuals with COPD face additional challenges - including higher nicotine dependence and psychological comorbidities - that complicate quit attempts. Methods: This mini-review summarises randomised controlled trials (RCTs) investigating smoking cessation interventions in COPD. Results: Our study reveals wide variability in the intensity, duration and components of interventions, with only a minority achieving long-term abstinence. Notably, two high-performing studies stand out for their comprehensive, long-term and individualised approaches. These findings suggest that success in smoking cessation for patients with COPD relies not only on the right intervention components but also on the construction, durability and sustained support. Conclusion: To support and sustain smoking cessation among patients with COPD, multicomponent, high-intensity and long-duration interventions tailored to individual needs appear to be required, with an emphasis on ongoing support and frequent follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.